Mechanisms of resistance to anti-BRAF treatments;Mécanismes de résistance aux inhibiteurs de BRAF

Annales de Dermatologie et de Venereologie

Volumn 141, Issue 11, 2014, Pages 671-681

  Charles, J ^a,b   Martel, C ^a   De Fraipont, F ^b   Leccia, M T ^a,b   Robert, C ^c   Busser, B ^a  

^a INSTITUT ALBERT BONNIOT   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

BRAF; Dabrafenib; Melanoma; Mutation; Resistance; Targeted therapy; Vemurafenib

Indexed keywords

B RAF KINASE INHIBITOR; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; DABRAFENIB; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; OXIME; SULFONAMIDE; VALINE; VEMURAFENIB;

ARTICLE; CANCER RESISTANCE; CLINICAL TRIAL (TOPIC); DRUG MECHANISM; HUMAN; MOLECULARLY TARGETED THERAPY; SYSTEMATIC REVIEW; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; GENETICS; MELANOMA; MUTATION;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; IMIDAZOLES; INDOLES; MELANOMA; MOLECULAR TARGETED THERAPY; MUTATION; OXIMES; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; VALINE;

EID: 84910135379     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annder.2014.06.021     Document Type: Short Survey

References (50)

1. Eggermont AM, Spatz A, Robert C. Cutaneous melanoma. Lancet 2014;383:816-27.
2. © Mélanome cutané métastatique - Rapport intégral.Boulogne-Billancourt: Coll. Avis & Recommandations, INCa;2013.
3. Fischer A, Hekman M, Kuhlmann J, Rubio I, Wiese S, Rapp UR.B- and C-RAF display essential differences in their binding to Ras: the isotype-specific N terminus of B-RAF facilitates Rasbinding. J Biol Chem 2007;282:26503-16.
4. Beeram M, Patnaik A, Rowinsky EK. RAF: a strategic target for therapeutic development against cancer. J Clin Oncol2005;23:6771-90.
5. Garnett MJ, Rana S, Paterson H, Barford D, Marais R. Wild-typeand mutant B-RAF activate C-RAF through distinct mechanismsinvolving heterodimerization. Mol Cell 2005;20:963-9.
6. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology andnew targeted therapy. Nature 2007;445:851-7.
7. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Lar-kin J, et al. Improved survival with vemurafenib in melanomawith BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
8. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S,et al. Mutations of the BRAF gene in human cancer. Nature2002;417:949-54.
9. Busser B, Leccia MT, Gras-Combe G, Bricault I, TemplierI, Claeys A, et al. Identification of a novel complex BRAFmutation associated with major clinical response to Vemura-fenib in a patient with metastatic melanoma. JAMA Dermatol2013;149:1403-6.
10. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W,Seiter S, et al. Randomized phase III study of temozolomideversus dacarbazine in the treatment of patients with advancedmetastatic malignant melanoma. J Clin Oncol 2000;18:158-66.
11. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, BonerandiJJ, et al. Fotemustine compared with dacarbazine in patientswith disseminated malignant melanoma: a phase III study. JClin Oncol 2004;22:1118-25.
12. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haa-nen JB, et al. Improved survival with ipilimumab in patientswith metastatic melanoma. N Engl J Med 2010;363:711-23.
13. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, GarbeC, et al. Ipilimumab plus dacarbazine for previously untreatedmetastatic melanoma. N Engl J Med 2011;364:2517-26.
14. Young K, Minchom A, Larkin J. BRIM-1, -2 and -3 trials: improvedsurvival with vemurafenib in metastatic melanoma patientswith a BRAF (V600E) mutation. Future Oncol 2012;8:499-507.
15. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R,Millward M, et al. Dabrafenib in BRAF-mutated metastaticmelanoma: a multicentre, open-label, phase 3 randomisedcontrolled trial. Lancet 2012;380:358-65.
16. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theu-rillat JP, et al. A landscape of driver mutations in melanoma.Cell 2012;150:251-63.
17. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, PochanardP, et al. Dissecting therapeutic resistance to RAF inhibi-tion in melanoma by tumor genomic profiling. J Clin Oncol2011;29:3085-96.
18. Van Allen EM, Wagle N, Sucker A, Treacy DJ, JohannessenCM, Goetz EM, et al. The genetic landscape of clinical resis-tance to RAF inhibition in metastatic melanoma. Cancer Discov2014;4:94-109.
19. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L,Kim JJ, et al. MEK1 mutations confer resistance to MEKand B-RAF inhibition. Proc Natl Acad Sci U S A 2009;106:20411-6.
20. Villanueva J, Infante JR, Krepler C, Reyes-Uribe P, Samanta M,Chen HY, et al. Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma.Cell Rep 2013;4:1090-9.
21. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhi-bitors transactivate RAF dimers and ERK signalling in cells withwild-type BRAF. Nature 2010;464:427-30.
22. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Ward-well L, Johnson LA, et al. COT drives resistance to RAFinhibition through MAP kinase pathway reactivation. Nature2010;468:968-72.
23. Paraiso KH, Haarberg HE, Wood E, Rebecca VW, Chen YA, XiangY, et al. The HSP90 inhibitor XL888 overcomes BRAF inhibitorresistance mediated through diverse mechanisms. Clin CancerRes 2012;18:2502-14.
24. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, et al. Acquired resistance to BRAFinhibitors mediated by a RAF kinase switch in melanoma canbe overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell2010;18:683-95.
25. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al.Melanomas acquire resistance to B-RAF (V600E) inhibition byRTK or N-RAS upregulation. Nature 2010;468:973-7.
26. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M,et al. Improved survival with MEK inhibition in BRAF-mutatedmelanoma. N Engl J Med 2012;367:107-14.
27. Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK,Levesque MP, et al. Modelling vemurafenib resistance in mela-noma reveals a strategy to forestall drug resistance. Nature2013;494:251-5.
28. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, et al.Melanoma whole-exome sequencing identifies (V600E) B-RAFamplification-mediated acquired B-RAF inhibitor resistance.Nat Commun 2012;3:724.
29. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C,Moriceau G, et al. RAF inhibitor resistance is mediatedby dimerization of aberrantly spliced BRAF (V600E). Nature2011;480:387-90.
30. Liu F, Cao J, Wu J, Sullivan K, Shen J, Ryu B, et al.Stat3-targeted therapies overcome the acquired resistanceto vemurafenib in melanomas. J Invest Dermatol 2013;133:2041-9.
31. Lesinski GB. The potential for targeting the STAT3 path-way as a novel therapy for melanoma. Future Oncol 2013;9:925-7.
32. Choi J, Landrette SF, Wang T, Evans P, Bacchiocchi A, BjornsonR, et al. Identification of PLX4032-resistance mechanisms andimplications for novel RAF inhibitors. Pigment Cell MelanomaRes 2014;27:253-62.
33. Wagenaar TR, Ma L, Roscoe B, Park SM, Bolon DN, Green MR.Resistance to vemurafenib resulting from a novel mutationin the BRAFV600E kinase domain. Pigment Cell Melanoma Res2014;27:124-33.
34. Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, TurajlicS, Niculescu-Duvaz D, et al. Inhibiting EGF receptor or SRCfamily kinase signaling overcomes BRAF inhibitor resistance inmelanoma. Cancer Discov 2013;3:158-67.
35. Shao Y, Aplin AE. BH3-only protein silencing contributes toacquired resistance to PLX4720 in human melanoma. Cell DeathDiffer 2012;19:2029-39.
36. Basile KJ, Abel EV, Aplin AE. Adaptive upregulation of FOXD3and resistance to PLX4032/4720-induced cell death in mutantB-RAF melanoma cells. Oncogene 2012;31:2471-9.
37. Abel EV, Basile KJ, Kugel 3rd CH, Witkiewicz AK, Le K, Ama-ravadi RK, et al. Melanoma adapts to RAF/MEK inhibitorsthrough FOXD3-mediated upregulation of ERBB3. J Clin Invest2013;123:2155-68.
38. Corazao-Rozas P, Guerreschi P, Jendoubi M, Andre F, JonneauxA, Scalbert C, et al. Mitochondrial oxidative stress is theAchille's heel of melanoma cells resistant to Braf-mutant inhi-bitor. Oncotarget 2013;4:1986-98.
39. Jiang X, Zhou J, Giobbie-Hurder A, Wargo J, Hodi FS. The acti-vation of MAPK in melanoma cells resistant to BRAF inhibitionpromotes PD-L1 expression that is reversible by MEK and PI3Kinhibition. Clin Cancer Res 2013;19:598-609.
40. Schilling B, Paschen A. Immunological consequences of selec-tive BRAF inhibitors in malignant melanoma: Neutralizationof myeloid-derived suppressor cells. Oncoimmunology 2013;2:e25218.
41. Sansal I, Sellers WR. The biology and clinical relevanceof the PTEN tumor suppressor pathway. J Clin Oncol2004;22:2954-63.
42. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Dam-sky Jr WE, et al. Braf (V600E) cooperates with PTEN loss toinduce metastatic melanoma. Nat Genet 2009;41:544-52.
43. Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC,et al. PTEN loss confers BRAF inhibitor resistance to melanomacells through the suppression of BIM expression. Cancer Res2011;71:2750-60.
44. Nathanson KL, Martin AM, Wubbenhorst B, Greshock J, LetreroR, D'Andrea K, et al. Tumor genetic analyses of patients withmetastatic melanoma treated with the BRAF inhibitor dabra-fenib (GSK2118436). Clin Cancer Res 2013;19:4868-78.
45. Deng W, Gopal YN, Scott A, Chen G, Woodman SE, Davies MA.Role and therapeutic potential of PI3K-mTOR signaling in denovo resistance to BRAF inhibition. Pigment Cell Melanoma Res2012;25:248-58.
46. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E,et al. Widespread potential for growth-factor-driven resistanceto anticancer kinase inhibitors. Nature 2012;487:505-9.
47. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR,Du J, et al. Tumour micro-environment elicits innate resistanceto RAF inhibitors through HGF secretion. Nature 2012;487:500-4.
48. Smalley KS, Lioni M, Dalla Palma M, Xiao M, Desai B, Egyhazi S,et al. Increased cyclin D1 expression can mediate BRAF inhibi-tor resistance in BRAF V600E-mutated melanomas. Mol CancerTher 2008;7:2876-83.
49. Maertens O, Johnson B, Hollstein P, Frederick DT, Cooper ZA,Messiaen L, et al. Elucidating distinct roles for NF1 in melano-magenesis. Cancer Discov 2013;3:338-49.
50. Whittaker SR, Theurillat JP, Van Allen E, Wagle N, Hsiao J,Cowley GS, et al. A genome-scale RNA interference screenimplicates NF1 loss in resistance to RAF inhibition. Cancer Dis-cov 2013;3:350-62.